Idylla EGFR Mutation Test (CE-IVD) 

Within 150 minutes and with less than 2 minutes hands-on time, the fully automated IdyllaTM EGFR Mutation Test covers 51 mutations in exons 18–21 in a single cartridge using only 1 FFPE tissue section from metastatic NSCLC showing a high concordance of >95% compared with reference methods.

Download technical sheet

Contact us for more information

Request demo

Catalog number: A0060/6

The Idylla™ EGFR Mutation Test contains PlexZyme and PlexPrime. More

Idylla EGFR Mutation Test

Specimen requirements

One of the biggest challenges in oncology biomarker testing is the ability to obtain samples of sufficient size and quality. With the IdyllaTM System only a minimal amount of sample is needed

  • 1x 5 μm FFPE tissue section
  • Neoplastic cells ≥10% -  if less, macrodissection is required

IDYLLA™ FIRST

Guiding First-Line Therapy Decisions in NSCLC

Idylla First Lung Leaflet

idylla_lung_leaflet.png

Idylla - From sample to treatment initiation in 1 to 2 days

The IdyllaTM Platform is a revolutionary, fully automated, molecular testing system designed to offer results in only 3 hours, shortening the time from sample to treatment initiation to 1 or 2 days.

Meet Idylla Request demo

Testimonial

Today, EGFR testing is a cumbersome process and it often takes several weeks before results are analyzed. This may lead to the administration of anti-EGFR therapy as second-line agents, which is less efficient than their use in first-line therapy. The IdyllaTM EGFR Mutation assay technology has the potential to change that; it is a cost-effective solution, ensuring reliable and fast detection of all relevant mutations.

Prof Giancarlo Troncone
University of Napoli Federico II, Naples, Italy

Prof Troncone

Idylla Oncology Assays

back to overview